Standards, Options and Recommendations for the use of appetite stimulants in oncology (2000) by Desport, J C et al.
Practice guideline
Standards, Options and Recommendations for the use of appetite
stimulants in oncology (2000)
JC Desport
1, G Gory-Delabaere
2, MP Blanc-Vincent
2, P Bachmann
3,JB e ´al
4, R Benamouzig
5, V Colomb
6,
D Kere
7, JC Melchior
8, G Nitenberg
9, B Raynard
10, S Schneider
11 and P Senesse
7
1CHU Dupuytren, Limoges, France;
2FNCLCC, Paris, France;
3Centre Le ´on Be ´rard, Lyon, France;
4Centre Oscar Lambret, Lille, France;
5Ho ˆpital Avicenne,
Bobigny, France;
6Ho ˆpital Necker, Paris, France;
7Centre Val d’Aurelle, Montpellier, France;
8Ho ˆpital Raymond Poincare ´, Garches, France;
9Institut Gustave
Roussy, Villejuif, France;
10Ho ˆpital Antoine Be ´cle `re, Clamart, France;
11Ho ˆpital de l’Archet, Nice, France
British Journal of Cancer (2003) 89(Suppl 1), S98–S100. doi:10.1038/sj.bjc.6601090 www.bjcancer.com
& 2003 FNCLCC
Keywords: neoplasms complications; appetite stimulants; practice guideline
                        
Anorexia and cachexia are serious complications frequently found
in patients with cancer (Bozetti, 1995; Donnelly and Walsh, 1995).
They are present in about 10% of patients at the time of diagnosis
(Bozetti et al, 1989). Multiple factors are involved in their aetiology
(Puccio and Nathanson, 1997). The resultant malnutrition is
associated with a poorer response to anticancer treatment and an
impaired quality of life (Holmes and Dickerson, 1987; Bozetti,
1995; De Conno et al, 1998). Many clinical trials have been
undertaken to evaluate the efficacy of drugs thought to be appetite
stimulants.
OBJECTIVES
The objective of these guidelines is to define which drugs have a
certain or probable appetite-stimulating effect, which ones have no
demonstrated effect and to describe any adverse effects in adult
patients with cancer. These guidelines do not cover specific clinical
cancer situations in which these drugs must be used.
METHODS
The details of the full methodology have been previously published
(Fervers et al, 2001). In summary, a multidisciplinary working
group was set up by the French National Federation of Cancer
Centres (Fe ´de ´ration Nationale des Centres de Lutte Contre le
Cancer–FNCLCC) to review the literature on the use of appetite
stimulants in oncology.
A literature search was performed in four database: Medline
s
(January 1990–June 1999), Cancerlit
s (January 1990–April 1999),
Embase
s (January 1990–July 1999) and the Cochrane Library
s
(1999, issue 2). The following key words were used: appetite
stimulants or anorexia/drug therapy or cachexia/drug therapy or
appetite associated with neoplasms. The list of references thus
identified was completed by the members of the working group
with pertinent references from their personal bibliographic
databases.
A total of 55 reports of randomised clinical trials, published in
English or French, evaluating the appetite-stimulating effect of
corticosteroids, synthetic progestogens and other drugs in cancer
patients were selected for these guidelines. Since appetite
stimulants are used to increase appetite in patients, this was the
primary outcome used in the analysis of the results in these trials.
The secondary outcomes were: improved quality of life; increase in
body weight; increased food consumption; decrease in nausea and/
or vomiting and improvement of anthropometric and biological
parameters. In the absence of the primary outcome (increased
appetite), none of the secondary outcomes are considered
sufficient to confirm an appetite stimulating effect.
After selection and critical appraisal of this literature, the
working group defined the ‘Standards’, ‘Options’ and ‘Recommen-
dations’ (SOR) for the use of appetite stimulants in patients with
cancer, based on a synthesis of the best available evidence.
‘Standards’ identify clinical situations for which there exist
strong indications or contraindications for a particular interven-
tion and ‘Options’ identify situations for which there are several
alternatives, none of which have shown clear superiority over the
others (Table 1). In any SOR, there can be several ‘Options’ for a
given clinical situation. ‘Recommendations’ enable the ‘Options’ to
be weighted according to the available evidence. Several interven-
tions can be recommended for the same clinical situation, so that
clinicians can make a choice according to specific clinical
parameters, for example, local circumstances, skills, equipment,
resources and patient preferences. The adaptation of the SOR to
the local situation is allowable if the reason for the choice is
sufficiently transparent and this is crucial for successful imple-
mentation. Inclusion of patients in clinical trials is an appropriate
form of patient management in oncology and is recommended
frequently within the SORs, particularly in situations where
evidence is too weak to support an intervention.
The type of evidence underlying any ‘Standard’, ‘Option’ or
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published models. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to the professional experience and consensus of the
expert group (‘expert agreement’).
These guidelines were then reviewed by a group of independent
experts (see the Appendix) and finalised after taking into
consideration their comments. This summary version is based
on an integral version that was validated and published in 2000
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These guidelines will be updated when new scientific data become
available or when there is a change in expert agreement.
Corticosteroids
Corticosteroids are appetite stimulants (level of evidence: B1).
There is insufficient information available to define the optimal
dose and scheduling for their use in this indication (recommenda-
tion).
Synthetic progestogens
Megesterol acetate Megesterol acetate is an appetite stimulant
(level of evidence: B1). It results in a significant increase in
appetite and there is a beneficial effect on body weight in patients
with cancer (standard, level of evidence: B1). The minimum
efficacious dose is 160mgday
1 (level of evidence: B1). If there is
no response, 480mgday
1, which seems to be the optimal dose,
can be used (recommendation, level of evidence: C). There is no
evidence that doses greater than 480mgday
1 have a higher
efficacy (level of evidence: B1).
Medroxyprogesterone acetate (MPA) Medroxyprogesterone acet-
ate is an appetite stimulant (level of evidence: B1). It results in a
significant increase in appetite (level of evidence: B1). The effect on
weight gain has not been confirmed (level of evidence: C).
Randomised clinical trials should be undertaken to investigate
the optimal dose and duration of administration of this drug,
although the minimum dose, shown to have a positive effect on
appetite in published trials was 200mgday
1 (recommendation,
expert agreement).
Other drugs
Cyproheptadine may be an appetite stimulant, but adverse effects
have been reported (level of evidence: C). Dronabinol, metoclo-
pramide, nandrolone and pentoxifylline have not been shown to
have any appetite-stimulating effects (level of evidence: C). These
drugs should not be used outside the setting of a randomised
clinical trial (recommendation, expert agreement). Hydrazine
sulphate is not an appetite stimulant (level of evidence: A).
Management strategy: appetite stimulants for use in
patients with cancer
Corticosteroids (no French product licence), megestrol acetate (no
French product licence) and MPA (French product licence) can be
used in the treatment of anorexia and weight loss in patients with
cancer (recommendation, level of evidence: B1). Appetite stimu-
lants can be used in combination with or after failure of dietetic
and oral nutritional management (recommendation, expert agree-
ment).
The use of appetite stimulants is particularly warranted in
patients with incurable disease (recommendation, level of evi-
dence: C). Appetite stimulants can be administered to patients with
any type of tumour (recommendation, expert agreement). The
optimal mode of administration for these products is not known.
Hydrazine sulphate should not be used (standard, level of
evidence: A).
Cyproheptadine, dronabinol, metoclopramide, nandrolone and
pentoxifylline should only be used in the setting of a randomised
clinical trial (standard, expert agreement).
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Table 1 Definition of Standards, Options and Recommendations
Standards Procedures or treatments that are considered to be of benefit, inappropriate or harmful by
unanimous decision, based on the best available evidence
Options Procedures or treatments that are considered to be of benefit, inappropriate or harmful by a
majority, based on the best available evidence
Recommendations Additional information to enable the available options to be ranked using explicit criteria (e.g.
survival, toxicity) with an indication of the level of evidence
Table 2 Definition of level of evidence
Level A
There exist a high-standard meta-analysis or several high-standard randomised clinical trials which give consistent results
Level B
There exist good quality evidence from randomised trials (B1) or prospective or retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous in their judgement
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